This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, J. Articles by Nisen, P. D. Search for Related Content PubMed PubMed Citation Articles by Chen, J. Articles by Nisen, P. D.

A Glial-specific, Repressible, Adenovirus Vector for Brain Tumor Gene Therapy¹

Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75235

The principle hurdles for gene therapy are selectivity and efficacy. Toward that end, we constructed an adenovirus gene delivery system to enable robust, glial-specific, and repressible ectopic expression. A replication-incompetent (E1-deleted) adenovirus 5 vector was modified by the addition of three tandem repeats of a 300-bp fragment enhancer region of the glial fibrillary acidic protein gene coupled to a minimal promoter sequence from human cytomegalovirus to drive a tetracycline-controlled transactivator. Using ß-galactosidase as a reporter gene, we demonstrated high level expression in cells of glial origin (including cell lines derived from glioblastoma multiforme) but no detectable expression in nonglial cells (neuroblastoma or fibroblasts). Furthermore, expression was tightly regulated by anhydrous tetracycline. To our knowledge, this is the first gene therapy delivery system that is glial specific and which also allows for repression of ectopic gene expression.

¹ This work was supported by Grant CA60173 from the NIH (to P. D. N.), the Klion Family Fund for Pediatric Research, and the HL Brown Fund for Childhood Brain Tumor Research.

² To whom requests for reprints should be addressed, at Abbott Laboratories, PPD, D-460, Building AP-10, 100 Abbott Park Road, Abbott Park, IL 60064-3500. Phone: (847) 938-7212; Fax: (847) 935-5165; E-mail: perry.nisen@abbott.com.

Received 11/ 6/97. Accepted 6/30/98.

This article has been cited by other articles:

				R. J. Mairs, S. C. Ross, A. G. McCluskey, and M. Boyd A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo J. Nucl. Med., September 1, 2007; 48(9): 1519 - 1526. [Abstract] [Full Text] [PDF]

				M. V. Lopez, P. Blanco, D. L. Viale, E. G. Cafferata, C. Carbone, D. Gould, Y. Chernajovsky, and O. L. Podhajcer Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Mol. Cancer Ther., October 1, 2006; 5(10): 2503 - 2511. [Abstract] [Full Text] [PDF]

				J. R. Smith-Arica, J. C. Williams, D. Stone, J. Smith, P. R. Lowenstein, and M. G. Castro Switching On and Off Transgene Expression within Lactotrophic Cells in the Anterior Pituitary Gland in Vivo Endocrinology, June 1, 2001; 142(6): 2521 - 2532. [Abstract] [Full Text] [PDF]

				X. Zheng, M. Johansson, and A. Karlsson Retroviral Transduction of Cancer Cell Lines with the Gene Encoding Drosophila melanogaster Multisubstrate Deoxyribonucleoside Kinase J. Biol. Chem., December 8, 2000; 275(50): 39125 - 39129. [Abstract] [Full Text] [PDF]